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Abstract
Background: Elevated intraocular pressure (IOP), as well as fluctuations in IOP, is a main risk factor for glaucoma,
but its pathogenic effect has not yet been clarified. Beyond the multifactorial pathology of the disease, autoimmune
mechanisms seem to be linked to retinal ganglion cell (RGC) death. This study aimed to identify if intermittent IOP
elevations in vivo (i) elicit neurodegeneration, (ii) provokes an immune response and (iii) whether progression of RGC
loss can be attenuated by the B lymphocyte inhibitor Belimumab.
Methods: Using an intermittent ocular hypertension model (iOHT), Long Evans rats (n = 21) underwent 27 unilateral
simulations of a fluctuating pressure profile. Nine of these animals received Belimumab, and additional seven rats
served as normotensive controls. Axonal density was analyzed in PPD-stained optic nerve cross-sections. Retinal cross-
sections were immunostained against Brn3a, Iba1, and IgG autoantibody depositions. Serum IgG concentration and IgG
reactivities were determined using ELISA and protein microarrays. Data was analyzed using ANOVA and Tukey HSD test
(unequal N) or student’s independent t test by groups.
Results: A wavelike IOP profile led to a significant neurodegeneration of optic nerve axons (−10.6 %, p < 0.001) and
RGC (−19.5 %, p = 0.02) in iOHT eyes compared with fellow eyes. Belimumab-treated animals only showed slightly
higher axonal survival and reduced serum IgG concentration (−29 %) after iOHT. Neuroinflammatory events, indicated
by significantly upregulated microglia activation and IgG autoantibody depositions, were shown in all injured retinas.
Significantly elevated serum autoantibody immunoreactivities against glutathione-S-transferase, spectrin, and transferrin
were observed after iOHT and were negatively correlated to the axon density.
Conclusions: Intermittent IOP elevations are sufficient to provoke neurodegeneration in the optic nerve and the retina
and elicit changes of IgG autoantibody reactivities. Although the inhibition of B lymphocyte activation failed to
ameliorate axonal survival, the correlation between damage and changes in the autoantibody reactivity suggests that
autoantibody profiling could be useful as a biomarker for glaucoma.
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Background
Glaucoma is one of the leading causes of blindness
worldwide, and the elevation of the intraocular pressure
(IOP) is considered a major risk factor [1–3]. However,
the pathology of glaucoma is multifactorial and defined
as a heterogenic optic neuropathy based on a slow pro-
gressive loss of retinal ganglion cells (RGC) [4]. Beside
other factors such as vascular dysfunction [5, 6], oxida-
tive stress [7], or retinal glutamate and nitric oxide tox-
icity [8, 9], inflammatory and autoimmune mechanisms
have been demonstrated to play an important role in the
pathobiology of RGC loss. These autoimmune mecha-
nisms are characterized by changes of autoantibody pat-
terns in the serum and aqueous humor of glaucoma
patients [10–12]. The observation of altered autoanti-
body profiles in glaucoma is not a unique phenomenon
among neurodegenerative diseases, as the humoral im-
mune system has also been implicated in the pathology
of Alzheimer’s dementia (AD) and Parkinson’s disease
(PD) [13]. Interestingly, AD and PD patients demon-
strate pathological changes in the retina and the optic
nerve, as well as in other areas of the visual system, lead-
ing to impairment of perception, color vision, or
contrast sensitivity [14, 15]. Some of the underlying
processes of neuronal degeneration, specifically RGC
loss in AD as well as PD, share similarities with glau-
coma [16, 17]. There are striking parallels between the
autoantibody reactions observed in AD, PD, and glau-
coma, such as those against glial fibrillary acidic protein
(GFAP), S100, and aldolase [11, 18]. However, there is
poor understanding of the origin or the primary event
that elicits the observed immune response in these neu-
rodegenerative disorders. The overall aim of this study is
to investigate whether an immune response, particularly
an autoantibody response, is initiated by short-term ele-
vations of the IOP in vivo.
A minimally invasive animal model was recently
established to induce intermittent ocular hypertension
(iOHT) [19, 20]. This new model was intended to be the
least invasive model to increase IOP experimentally in
rats and to avoid a strong artificial immune response
due to inflammation likely occurring in more invasive
approaches, such as the bead occlusion or laser photo-
coagulation. Using this experimental glaucoma animal
model, it is assumed that the predominant changes of
the humoral immune system occur in response to the
applied pressure and/or to the subsequent loss of RGCs.
An increasing number of studies indicate a link between
the fluctuation of the IOP in glaucoma patients and dis-
ease progression [21, 22]; the advantage of this new
model is to mimic these dynamic IOP variations.
If it emerges that changes of the humoral immune re-
sponse and a loss of RGC can be initiated by a wavelike
profile of intermittent ocular hypertensions in vivo, the
question of whether or not the subsequent humoral im-
mune response affects the progression of RGC loss can
be addressed. Moreover, a pharmaceutical modulation of
the B lymphocyte population could have an influence on
RGC survival. To test this, Belimumab, an inhibitor of
the B lymphocytes activating component of the tumor
necrosis factor family (BAFF), was applied to one experi-
mental group before and during IOP elevations to deter-




Animals were treated according to the ARVO Statement
for the Use of Animals in Ophthalmic and Vision
Research, and all experiments have been approved by
the national investigation office in Koblenz, Germany
(23 177-07/G 11-1-029). Eight-week-old male Long
Evans rats were obtained from Charles River (Sulzfeld,
Germany) and housed in climate-controlled rooms
under 12-h light-dark cycles and received food and water
ad libitum. Twenty-eight animals were assigned to
three groups: CTRL (n = 7), iOHT (n = 12), and iOHT+
Belimumab (n = 9).
Intraocular pressure measurement
In order to detect any additional changes to IOP that
may have occurred in response to the manipulations,
IOP was monitored routinely in awake animals between
9 am and 12 pm using a TonoLab tonometer (icare,
Espoo, Finland). Rats were kept in a horizontal orienta-
tion with the head in a relaxed position. No pressure
was applied to the head during measurement. The ani-
mals became habituated to the IOP measurements
quickly. All measurements were performed by the same
examiner, and a mean value was calculated from ten
consecutive measurements. IOP values that were identi-
fied as inaccurate by the TonoLab device were not
included in the analysis. The IOP measurements in anes-
thetized rats were performed immediately before and
after onset or adjustment of the loop as well as every five
minutes throughout the manipulation. The ΔIOP was
defined as the integrated IOP to which the eyes were ex-
posed during the intermittent periods of iOHT. It was
calculated from the ∑ of areas under the curve after sub-
traction of IOP values of the fellow eye.
Experimental setup
In accordance with the previously described technique
for minimally invasive short-term IOP elevations [19, 20],
iOHT was conducted in a wavelike profile. Adjusting a
silicone loop around the limbus of the right eye (Fig. 1a),
it is possible to narrow the anterior iridocorneal angle
without modifying the shape of the eye or inducing
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subsequent structural injuries to the eye, which was moni-
tored by regular funduscopy. In contrast to the first de-
scription of this method by Joos [19], the loop was not
placed posterior to the limbus, but around the limbus.
The loop slightly compresses Schlemm’s canal and the
episcleral veins (Fig. 1b’) and provokes a marginal reloca-
tion of the iridocorneal angle, resulting in an increase
of aqueous humor outflow resistance. Rats were anes-
thetized using 0.185 ml/kg body weight medetomidine
(Dorbene vet., Pfizer, New York, NY, intramuscular
administration), and eyes received oxybuprocain (Novesine
0.4 %, OmniVision, Puchheim, Germany) prior to,
and regularly during, the procedure. Fellow eyes were
covered with dexpanthenol to avoid corneal dehydration
and prevent superficial irritations (Bepanthen, Bayer,
Leverkusen, Germany). Once the loop is attached around
the eye, the IOP rises immediately but returns to baseline
levels within minutes when no adjustment of the loop oc-
curs [20]. If the mean IOP was lower than the desired
level, the diameter of the loop was slightly decreased.
Conversely, the diameter was increased by gentle release
of the loop when the mean IOP was too high. To mimic
IOP fluctuations, which is a common observation in glau-
coma patients, a wavelike IOP profile was applied to the
animal’s eyes. This profile consists of three intervals of
20 min to 35 mmHg (interval I), 45 mmHg (interval II),
and again to 35 mmHg (interval III). The loop was re-
moved for 10 min between intervals II and III to simulate
a pressure drop to a physiologic IOP level (Fig. 2a). The
IOP elevation was performed on five consecutive days
followed by 2 days of rest for 5 weeks. In week 6, IOP was
elevated on two consecutive days and animals were
sacrificed afterwards. Thus, each animal received a
total of 27 unilateral IOP elevations. One group received
IOP elevation (iOHT), while another group received
10 mg/kg of the B lymphocyte inhibitor Belimumab
(Benlysta, GlaxoSmithKline, Parma, Italy, intravenous
administration), initially 3 days before the first iOHT
and weekly throughout the study in addition to IOP
elevations as described above (iOHT + Belimumab).
Control animals underwent the same examinations in
a corresponding time frame but were not subjected to
iOHT injury (CTRL).
After the final in vivo experiments, all animals were
euthanized by CO2 inhalation followed by cardiac blood
withdrawal and cardiac perfusion with 4 % paraformal-
dehyde/heparin (PFA, 2000 U/l) solution (Histofix, Roth,
Karlsruhe, Germany). Eyes were marked in the nasotem-
poral orientation, dissected, immersion-fixed in 4 %
PFA, and embedded in paraffin. Optic nerves with the
optic chiasm attached were harvested, preserved in
3 % glutaraldehyde/0.1 mol/l sodium cacodylate buffer
(Merck, Darmstadt, Germany) and processed for epoxy
resin embedding.
Quantification of axonal loss in optic nerves
0.7 μm semithin transverse optic nerve sections,
taken 2 mm distal to the optic chiasm, were stained
with p-phenylenediamine (PPD), and quantification of
the axon density was performed as described previously
[20, 23]. Briefly, 15 images from one representative sec-
tion per optic nerve were captured in a predetermined
crosswise pattern at ×10 magnification (2 C). This sam-
pling method covers 32 % of the total optic nerve section.
The semi-automated algorithm for quantification of the
axon density using ImageJ software (NIH, Bethesda,
MD, USA) contained the following steps: (1) images
were converted into 8-bit format; (2) the automated
threshold setting was verified and corrected manually
by an independent observer masked to the animals’
status; and (3) numbers of axons were finally deter-
mined using a macro for the particle analyzer. Axon











Fig. 1 Intermittent ocular hypertension: Induction of short-term elevated intraocular pressure. a Eyes of anesthetized Long Evans rats were injured
by inducing elevated intraocular pressure levels using a silicone loop around the bulb for 1 h per day for 27 treatments. The loop is attached very
gently around the eye without modifying the shape of the eye (white arrow) and held in place using a stand. Eyes were kept moist during the
time of the experiment. Left eyes served as fellow control eyes. b A schematic of the anatomic details of a rodent eye without (b) and with the
loop attached (b’). The loop slightly compresses Schlemm’s canal (SC) as well as the episcleral veins (in lighter gray) and provokes a marginal
relocation of the iridocorneal angle (indicated by the arrow), resulting in an increase of aqueous humor outflow resistance. Abbreviations: C cornea,
I iris, CB ciliary body, S sclera
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RGC analysis and immunedetection of IgG autoantibodies
and microglia
For each staining procedure, five 10 μm sagittal sections
per eye were dewaxed, rehydrated, and blocked for en-
dogenous peroxidase in 0.5 % H2O2 solution for 30 min.
RGC labeling, microglia, and immunoglobulin G (IgG)
autoantibody detection were conducted in accordance
with routine procedures [24, 25]. Brain-specific homeo-
box/POU domain protein 3A (Brn3a) immunostaining
was used as a RGC marker [26, 27]. Slides underwent
antigen retrieval in target retrieval solution (TRS,
DAKO, Hamburg, Germany) for 50 min at 70 °C and
blocked in 2 % BSA/ 0.1 % Triton X-100/PBS solution
(all Sigma) for 60 min. A goat anti-Brn3a antibody (C20,
St. Cruz Biotechnology, Santa Cruz, CA, USA) was di-
luted 1:400 in blocking buffer, and specimens were incu-
bated overnight at 4 °C. Sections were washed in PBS,
and a horseradish peroxidase (HRP) conjugated rabbit
anti-goat IgG (DAKO) diluted 1:400 in PBS was applied
for 3 h at room temperature.
Fig. 2 Intermittent intraocular hypertension and analysis of the optic nerve axon density. a An exemplary profile of 12 iOHT eyes conducted at
the ninth day of the experiment shows the effective mean IOP (ordinate) during simulation of a 1-h wavelike IOP profile (abscissa). IOP reduces to
10 mmHg after anesthesia, and IOP is raised to 35 mmHg for 20 min (interval I), followed by 45 mmHg for another 20 min (interval II). The loop
was released to simulate a pressure drop. IOP was reset to 35 mmHg for 20 min (interval III), and IOP decreased to 12.5 mmHg during recovery
phase. Arrows indicate important pressure changes before and after iOHT. b The survival of optic nerve axons was evaluated as the number of
axons in an area of 0.05 mm2. Injured eyes of iOHT group showed a significant loss of optic nerve axons compared with fellow eyes in the same
group (gray bar, p < 0.01) and control eyes (black bar, p < 0.01). Additionally, axon densities of injured eyes of iOHT group were significantly reduced
compared with fellow eyes of iOHT + Belimumab group (grey bar, p < 0.01) but not to injured eyes of the iOHT + Belimumab group (horizontal lines,
p = 0.05). Note that no significant loss of axonal density was observed for injured eyes of the Belimumab-treated group compared with fellow eyes
(p = 0.5) and with control eyes (p = 0.07). Significances are indicated as follows: **p < 0.01. c A representative p-phenylenediamine-stained
ultrathin transverse cross-sections (×10 magnification) shows the area where 15 high-resolution pictures were taken for the optic nerve
axon density analysis. In total, 32 % of the optic nerve was analyzed for axon density survival. Scale bar represents 200 μm. d–h Representative high-
resolution images (×100 magnification) show different stages of degeneration in optic nerve cross-sections. Healthy axons were present in control
optic nerves (ON, d), while fellow eyes of iOHT ON (e) and iOHT + Belimumab (g) showed a slight damage, including swollen and collapsing axons
indicated by arrows. Major axon degeneration with bulged myelin sheaths around axons (arrows) and gliotic areas (triangle) were observed in injured
ONs of iOHT group (f) and iOHT + Belimumab group (h). Scale bar represents 20 μm
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For immunolabeling of ionized calcium binding adaptor
molecule 1 (Iba1), slides were blocked with 0.25 % NGS/
0.5 % BSA/0.1 % Triton X-100/PBS after TRS antigen
retrieval for 30 min at 90 °C. Rabbit anti-Iba1 (WAKO
chemicals GmbH, Neuss, Germany, 1:5000) primary anti-
body was diluted in 0.1 % Triton X-100/PBS. After over-
night incubation at 4 °C, sections were washed in PBS
followed by goat anti-rabbit IgG (H + L) chain specific
HRP-conjugated (Calbiochem, Merck KGaA, 1:1000,
60 min) secondary antibody incubation.
For IgG autoantibody staining, slides were boiled in
TRS solution for 45 min at 90 °C and blocked in 1 %
BSA/0.1 % Triton X-100/PBS solution for 10 min. A
goat anti-rat IgG HRP-conjugated antibody (Thermo
Scientific, Waltham, MA, USA) was diluted 1:500 in
blocking buffer, and sections were incubated overnight.
After several wash steps in PBS, 3,3′-diamicobenzidin
(DAB, DCS diagnostics, Hamburg, Germany) incubation
for 10 min followed for color development. All sections
were counterstained with hematoxylin, dehydrated, and
coverslipped. For image acquisition, an Eclipse TS 100
microscope (Nikon, Yurakucho, Tokyo, Japan) with a
DS-Fi1-U2 digital microscope camera (Nikon) and an
ELWD 20x/0.45 S Plan Flour Ph1 ADM objective
(Nikon) was used and recorded by the imaging software
NIS Elements (Nikon, Version 4.10 64 bit). Images were
transferred to CorelDRAW X4 Graphic Suites (Corel
Corporation, Ottawa, Canada).
Data for each parameter was obtained from four repre-
sentative cross-sections for each eye, containing the
optic nerve head to ensure corresponding retinal pos-
ition. The number of cells is calculated per 1-mm retinal
length.
Determination of serum IgG concentration
Blood samples from the cardiac blood withdrawal were
allowed to clot at room temperature and were centri-
fuged at 10 °C for 10 min and 4000 rpm. Individual
serum IgG concentrations of all animals were deter-
mined using a rat IgG ELISA kit (Genway, San Diego,
CA, USA) according to the manufacturer’s protocol.
Remaining serum samples were stored at −20 °C for
further analysis of the antibody pattern.
Antigen microarray assay
Using a non-contact array spotter (sciFLEXARRAYER 3,
Scienion, Berlin, Germany), ten antigens (Additional file 1:
Table S1) of interest were spotted in triplicates on nitro-
cellulose covered glass slides (Oncyte, nitrocellulose 16
multi-pad slides, Grace Bio-Labs, Bend, OR, USA). Block-
ing (0.5 % bovine serum albumin (BSA, Sigma, Steinheim,
Germany) of unspecific binding sites of the nitrocellulose
membrane in 0.5 % Tween 20 in phosphate buffered
saline, (PBS-T, Gibco Life Technologies, Carlsbad, CA,
USA) was performed for 1 h. Slides were incubated with
animal’s serum taken at the end of the study (1:100 in
PBS), and the assay was run as described previously [28].
Resulting antigen-antibody complexes were visualized by
the use of the secondary antibody goat anti-rat IgG
(H + L) Cy5 (Invitrogen, Carlsbad, CA, USA; 1:250 in
PBS) Finally, slides were spin-dried (SpeedVac Con-
centrator 5301; Eppendorf, Hamburg, Germany), and
emitted fluorescence signals were scanned using a
high-resolution confocal array scanner (Affymetrix 428,
Santa Clara, CA, USA).
For image and data processing, digitized signals (TIFF
files) were analyzed with Imagene 5.5 (BioDiscovery Inc.,
Los Angeles, CA, USA). Technically faulty spots were
identified by visual inspection and removed from the
data set. For each spot, the local background intensity
was subtracted from the median spot intensity. Intensity
of the three technical replicates for each antibody was
averaged and used for statistical analysis.
Statistical analysis
For multiple test schemes, Tukey’s HSD post hoc
(unequal N) tests were used. Comparison between two
groups was performed using student’s independent t test.
Data mining of microarray experiments was performed
using one-way ANOVA and post hoc testing [28]. The
correlation coefficient r was determined correlating the
number of axons and the individual relative intensities
per antigen. P values <0.05 were considered significant.
Data are given as mean ± standard deviation (SD) or as
group median. All statistical analyses were performed by
Statistica Version 12 (Dell Inc. Round Rock, TX, USA).
Results
IOP in awake rats and exposure to elevated IOP
The IOP values of awake animals stayed within the nor-
mal physiological range of 10 and 13.3 mmHg and dis-
played no significant changes throughout the study
(Additional file 2: Table S2). Additionally, IOP was re-
corded during procedures of iOHT in anesthetized ani-
mals. These IOP data were cumulated to display the
total ΔIOP exposure in injured eyes over the fellow eyes
[20, 29]. In total, 27 wavelike, 60 min-long IOP eleva-
tions led to a ΔIOP exposure of 748 ± 12 mmHg. The
treatment with Belimumab did not interfere with the in-
duction of iOHT and revealed a similar ΔIOP exposure
of 756 ± 20 mmHg (p = 0.26).
Intermittent IOP elevation alters optic nerve axon
numbers and RGC density
Analysis of the axon density in the optic nerves revealed
a loss of −11.9 % (p < 0.001) in iOHT injured eyes
and −1.5 % in iOHT fellow eyes compared with con-
trol eyes. Belimumab-treated animals showed axonal loss
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of −1.9 % in iOHT+ Belimumab fellow eyes and −7.5 % in
iOHT+ Belimumab injured eyes compared with control
eyes. Injured eyes of the iOHT+ Belimumab group re-
vealed a slightly higher axonal density (+4.9 %) compared
with iOHT group, even though this was not statistically
significant (independent t test: p = 0.12, Fig. 2b, Table 1).
Optic nerves obtained from untreated control animals
and from uninjured fellow eyes showed minimal signs of
neurodegeneration, such as swollen myelin sheaths, rup-
tured axons or gliosis (Fig. 2d, e, and g). Frequent axonal
damage and some gliotic formations were only observed
in optic nerve sections in eyes which underwent iOHT
(Fig. 2f, h), independent of whether animals were with-
out medication or received Belimumab.
Examination of the RGC density recapitulated the re-
sults of the optic nerve axon analysis. Eyes of control an-
imals (Fig. 3b) and those exposed to iOHT displayed
normal retinal morphology (Fig. 3c–f ), but a significant
loss of −19 % of RGC compared with the RGC density
of their fellow uninjured eyes (p = 0.02), or to RGC num-
bers of control animals (−30.5 %, p = 0.0001, Fig. 3a,
Table 1). Additionally, contralateral eyes of the iOHT
group showed a slight, but not significant, loss of RGC
compared with controls. Belimumab-treated animals
displayed decreased RGC density in eyes after iOHT. As
was the case for axonal density, the RGC loss was not
statistically significant in comparison to the fellow eyes
(p = 0.76).
Morphometry and distribution of microglia and IgG
autoantibody depositions in the retina
To detect activation of retinal microglia, immunohistolo-
gical staining of retinal cross-sections was performed
and showed the occurrence of Iba1-positive cells in al-
most all retinal layers. In comparison to the control
group, the amount of Iba1-positive cells was significantly
higher in the eyes of the iOHT group (p < 0.03) and
virtually identical to numbers found in animals which
received iOHT + Belimumab treatment (p = 0.99, Fig. 4a,
Table 1). The majority of microglia cells in the eyes of
the iOHT groups that were located in the ganglion cell
layer displayed an amoeboid phenotype (Fig. 4c–f, inset),
while microglia in controls showed a ramified morph-
ology with high numbers of long and thin processes
(Fig. 4b, inset). Likewise, microglia cells of the inner
plexiform layers and outer retinal layers exhibited a uni-
form, ramified morphology in all groups.
When determining the percentile distribution of
microglia in retinal layers, the main appearance of
microglia in control eyes was in the ganglion cell layer
(44 %) as well as in the inner nuclear layer (35 %). Des-
pite an increase of the total number of microglia in the
iOHT group, their distribution was as observed in con-
trol eyes. In the iOHT + Belimumab group, a larger
fraction of microglia was found in the ganglion cell layer
of the injured eye (60 %), as well as the uninjured con-
trol eyes (58 %, p < 0.01 compared with control eyes and
iOHT injured eyes and p < 0.05 compared with iOHT
fellow eyes). Conversely, a significant reduction of
microglia in the inner nuclear layer to 20 and 22 % in
Belimumab-treated eyes occurred compared with iOHT
fellow eyes (p < 0.01) or to iOHT injured eyes (p < 0.05).
Apparently, a redistribution of microglia from the inner
nuclear layer to the ganglion cell layer occurred in the
eyes of Belimumab-treated animals (Fig. 4g, Additional
file 3: Table S3).
The analysis of retinal IgG autoantibody depositions
revealed twice the amount of autoantibodies in the eyes
of iOHT animals compared with controls and a more
modest increase of autoantibody deposits in eyes of ani-
mals that received Belimumab (Fig. 5a, Table 1). The
majority of these were located in the ganglion cell layer,
and extravasal IgG autoantibody depositions were easily
identified based upon their dense formations in the ab-
sence of blood vessel. No IgG autoantibody depositions
were observed in the outer nuclear layer. In comparison
to control eyes with 0.5 ± 0.4 IgG autoantibody deposi-
tions per mm retina, the number of IgG autoantibody
depositions was significantly higher in eyes that under-
went iOHT (1.3 ± 0.6, p = 0.002) as well as in fellow eyes
(1.1 ± 0.4, p = 0.045). Animals that received Belimumab
showed higher, though not statistically significant, levels
of IgG autoantibody depositions in iOHT eyes (0.9 ± 0.4,
p = 0.3) as well as in their fellow eyes (0.9 ± 0.2, p = 0.3,
Fig. 5b–f ) compared with control eyes.
Influence of IOP elevations on the humoral immune
response
The serum IgG titer of each group was quantified by
ELISA. Control rats at the age of 14 weeks had a mean
IgG titer of 2.55 ± 0.66 ng/ml. iOHT animals showed a
similar level of IgG at 2.74 ± 0.38 ng/ml (p = 0.72).
The administration of Belimumab significantly re-
duced the IgG titer to 1.80 ± 0.24 ng/ml in compari-
son to control animals (p = 0.02) and to iOHT-treated
animals (p = 0.003).
Antigen microarray analysis revealed significantly
altered IgG autoantibody reactivities against the anti-
gens glutathione S-transferase (CTRL: 18,280 ± 5752 U,
iOHT: 49,091 ± 12,184 U, iOHT + Belimumab: 29,301 ±
11,925 U), spectrin (CTRL: 5391 ± 2519 U, iOHT: 9876 ±
2850 U, iOHT + Belimumab: 5429 ± 2323 U), and transfer-
rin (CTRL: 18,055 ± 3682 U, iOHT: 33,020 ± 10,789 U,
iOHT + Belimumab: 19,680 ± 4974 U). All of these
changes were statistically significant when compared
between iOHT and controls (glutathione S-transferase:
p = 0.0002, spectrin: p = 0.006, transferrin: p = 0.003).
Treatment of animals with the B lymphocyte inhibitor
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Table 1 Summary of the densities of the axons, retinal ganglion cells, microglia, and IgG depositions
Group Number of axons
per 0.05 mm2 ± SD

















p vs iOHT injured
eye
IgG depositions






Control eyes 22,267 ± 1408 (12) 0.0003 95.2 ± 12.6 (13) 0.0001 5.2 ± 1.1 (14) 0.01 0.5 ± 0.4 (14) 0.002
iOHT fellow eye 21,943 ± 1510 (12) 0.98 0.001 82.0 ± 9.9 (11) 0.07 0.02 6.7 ± 1.3 (10) 0.03 1 1.1 ± 0.4 (10) 0.045 0.75
iOHT injured eye 19,624 ± 1709 (12) 0.0003 66.0 ± 13.2 (11) 0.0001 6.7 ± 1.3 (12) 0.01 1.3 ± 0.6 (10) 0.002
iOHT + Belimumab
fellow eye
21,838 ± 802 (9) 0.96 0.008 80.9 ± 10.0 (9) 0.08 0.06 6.6 ± 1.0 (9) 0.08 0.99 0.9 ± 0.2 (9) 0.3 0.3
iOHT+ Belimumab
injured eye
20,593 ± 609 (9) 0.07 0.5 74.2 ± 9.5 (8) 0.005 0.6 6.5 ± 1.0 (8) 0.1 0.99 0.9 ± 0.4 (8) 0.3 0.4
Analysis after 27 treatments using intermittent ocular hypertension shows the number of axons per 0.05 mm2 for all groups. These data illustrate the damage of optic nerves, and the number of Brn3a-positive cells indicate
the overall density of retinal ganglion cells. Furthermore, the Iba1-positive cells imply the activation of microglia and immunoglobulin G (IgG) depositions, displaying the occurrence of autoantibody depositions. Brn3a, Iba1,















Belimumab led to significantly decreased immunoreactivity
compared with iOHT animals (glutathione S-transferase:
p = 0.001, spectrin: p = 0.002, transferrin: p = 0.003,
Fig. 6a–c, left row). Importantly, statistically significant
changes of the autoantibody reactivity between animals
that received Belimumab and controls were not observed.
A correlation analysis between the number of optic
nerve axons and the relative intensities for specific
antibody-antigen reactions was performed. The results
showed that the immunoreactivity against glutathione
S-transferase (r = −0.56, p = 0.003), spectrin (r = −0.42,
p = 0.03), and transferrin (r = −0.69, p = 0.0001, Fig. 6a–c,
right row) in iOHT animals were negatively correlated
to their respective axon densities. Accordingly, lower
immunoreactivities of antibodies against glutathione
S-transferase, spectrin, and transferrin corresponded
to higher axonal survival after iOHT.
Discussion
This study allows the following six conclusions re-
garding retinal injury and the involvement of immune
responses in this rat model of intermittent ocular
hypertension:
(i) iOHT elicits neurodegeneration in the optic nerve
and the retina, although the fluctuating IOP
pattern does not have more destructive potential
than constantly elevated IOP.
(ii) Retinas of contralateral, uninjured eyes display
pathological changes in comparison to untreated
control eyes.
(iii) Retinal microglia in iOHT eyes are enriched in the
retinal ganglion cell layer and activated.
(iv) iOHT eyes accumulate IgG autoantibody depositions
in the retina.
Fig. 3 Retinal ganglion cell analysis. a The survival of retinal ganglion cells was analyzed as the number of Brn3a-positive cells per mm retina in
naso-temporal cross-sections of the eye. A significant loss of retinal ganglion cells was observed in injured eyes of iOHT group and iOHT + Beli-
mumab group (both p < 0.01, horizontal lines) compared with control eyes (black). Furthermore, a significant difference in damage was observed
between fellow and injured eye of iOHT group (p < 0.05), but not between both eyes of iOHT + Belimumab group (p = 0.8). Significant values are
indicated as follows: *p < 0.05, **p < 0.01. b–f Representative images of retinal cross-sections (×20 magnification) show different densities of
Brn3a-positive cells (arrows) in controls (CTRL, b), fellow and injured eyes of iOHT group (c and d, respectively), and fellow and injured eyes of
iOHT + Belimumab group (e and f, respectively). Images were taken at the same eccentricity to the optic nerve head to ensure comparability.
Note the low number of retinal ganglion cells in injured eyes. Abbreviations: GCL ganglion cell layer, INL inner nuclear layer, ONL outer nuclear
layer, CHO choroid. Scale bar represents 100 μm. Significant values are indicated as follows: *p < 0.05, **p < 0.01
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Fig. 4 (See legend on next page.)
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(v) Serum autoantibody reactivities against glutathione-
S-transferase, spectrin, and transferrin significantly
increased and might serve as biomarkers.
(vi) Repeated injections of the B lymphocyte
inhibitor Belimumab have very little effect on
neurodegeneration, deactivation of microglia, and
reduction of IgG autoantibody depositions despite
lowering the total IgG serum concentration.
The main risk factor for glaucoma is elevated IOP [1–3].
In this study, a silicone loop was attached around the
limbus of the eye to temporarily increase the IOP.
After the manipulation, the IOP values returned to
baseline levels, which demonstrates that this model
does not cause angle-closure glaucoma. In this glau-
coma animal model, a total ΔIOP exposure of 748 to
756 mmHg was achieved during 27 IOP elevations
(See figure on previous page.)
Fig. 4 Activation of microglia and analysis of the distribution in the retina. a The activation of microglia was analyzed as Iba1-positive cells per mm
retina in naso-temporal cross-sections of the eye. After iOHT, a significant increase of microglia occurred in fellow and injured eyes (both p < 0.05)
compared with control eyes. No significant changes were observed for Belimumab-treated animals. Significant values are indicated as follows:
*p < 0.05. b–f Representative images of retinal cross-sections (×20 magnification) show the numbers and distribution of Iba1-positive cells (arrows)
in diverse retinal layers in control (CTRL, b), fellow and injured eyes of iOHT group (c and d, respectively), and fellow and injured eyes of
iOHT + Belimumab group (e and f, respectively). Magnifications of representative microglia show a transformation from non-activated ramified
phenotype with long ramifications in controls (b) to an activated, amoeboid phenotype in injured eyes (d, f). g Percentile distribution of microglia cells
in retinal layers are given for all groups. Data were normalized in relation to the difference of the total number of microglia between the groups.
Significant values are indicated as follows: *p < 0.05, **p < 0.01. Abbreviations: GCL ganglion cell layer, IPL inner plexiform layer, INL inner nuclear layer,
OPL outer plexiform layer, ONL outer nuclear layer, CHO choroid. Scale bar represents 100 μm
Fig. 5 Analysis of IgG autoantibody depositions. a Autoantibody depositions were analyzed as immunoglobulin G (IgG)-positive depositions per mm
retina in naso-temporal cross-sections of the eye. A significant increase of IgG autoantibody depositions could be observed in fellow and injured eyes
of the iOHT group (p < 0.05 and p < 0.01, respectively) compared with control eyes, but not in iOHT + Belimumab group. Significant values are
indicated as follows: *p < 0.05, **p < 0.01. b–f Representative images of retinal cross-sections (×20 magnification) show distinct IgG-positive depositions
(arrows) in the ganglion cell layer of the retina. Magnifications highlight the dense morphology of these depositions (b, d, and f). Triangles indicate
IgG-positive blood vessels containing erythrocytes, which must not be confused with IgG depositions. Abbreviations: GCL ganglion cell layer, INL inner
nuclear layer, ONL outer nuclear layer, CHO choroid. Scale bar represents 100 μm. Significant values are indicated as follows: *p < 0.05, **p < 0.01
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Fig. 6 Systemic immune response. Quantification of different antigen reactivities of control animals (CTRL), animals that received unilateral intermittent
ocular hypertension (iOHT), and animals with unilateral intermittent ocular hypertension which received Belimumab treatment (iOHT + Belimumab).
The left side (a–c )shows the immunoreactivities in relative intensities [U] per group against glutathione S-transferase (a), spectrin (b), and
transferrin (c). Each triangle represents one animal, and the black line indicates the group median. Compared with the relative intensity of
CTRL, iOHT was significantly upregulated (**, p < 0.01) for all investigated antigens. Compared with iOHT, all immunoreactivities of iOHT + Belimumab
were significantly downregulated (##p < 0.01). All p values were calculated by Tukey’s HSD post hoc test (unequal N). Scatterplots of the number of
optic nerve axons in a distinct area (no. of axons/0.05 mm2) against relative intensities of glutathione S-transferase (a), spectrin (b), and transferrin (c)
are shown on the right side. For correlation analysis, p values lower than 0.05 were considered as significant. The correlation coefficient r
ranged between −0.42 and −0.69 for the investigated antibody reactivities (shown in upper right corner of the diagrams). The gray fitting
line shows the negative linear dependence between the number of axons per 0.05 mm2 and the relative intensities. CTRLs are represented
as empty circles, iOHT as empty triangle, and iOHT + Belimumab as filled triangle. Significant values are indicated as follows: **p < 0.01 compared with
control group, ##p < 0.01 compared with iOHT group
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without affecting the IOP of the contralateral fellow
eye. Intermittent ocular hypertension in a wavelike
profile causes neuroretinal degeneration, which was indi-
cated by the loss of axonal density by −10.6 % in injured
optic nerves and decline of Brn3a+ cells by −19.5 %. Inter-
estingly, these findings are comparable to those from a
previous study with similar parameters (duration, animals,
experimental setup), but a static IOP elevation [20]. Even
though the mean ΔIOP exposure (752 ± 16 mmHg;
iOHT and iOHT + Belimumab) in this study is slightly
higher than the ΔIOP exposure during the previous
study (737 ± 10 mmHg), the rate of axonal loss in the
optic nerves is similar in both studies (−17 %). Thus,
a relationship between the fluctuating IOP patterns
and the progression of RGC loss could not be proven.
Degeneration of optic nerve axons, and RGC, seems
to be primarily driven by IOP elevations themselves
rather than by fluctuations of the IOP. In this model,
neurodegeneration accounts for −10.6 % optic nerve
axonal loss and −19.5 % RGC loss, which is comparable to
another rat glaucoma model by Semdowski et al. [30]. In
their model, polystyrene microbeads are injected intravi-
treally and lead to IOP levels between 20 to 40 mmHg
over 6 weeks. Due to the higher cumulative IOP exposure,
neurodegeneration accounts for −25 % optic nerve axonal
loss and −34 % RGC loss.
Immune response in the neural retina
Activation of retinal microglia is a characteristic finding
in IOP-associated animal models of glaucoma [31–34].
Interestingly, a bilateral activation of microglia in the
retina and optic tract after unilateral IOP elevation has
been reported in several studies [32–35]. Likewise, a sig-
nificantly increased amount of microglia not only in eyes
after elevation of the IOP but also in contralateral, unin-
jured eyes was also observed in this study. The majority
of microglia in retinas displayed a transformed amoeboid
phenotype with a dense cell body and sparse but thick
ramifications (Fig. 4d), indicating activation of these im-
munocompetent cells. Microglia function during retinal
degeneration is controversial, and activation of microglia
cells should not be equated to being detrimental for
neuronal survival per se. Moreover, microglia activation
includes self-regulatory mechanisms to counterbalance
over-activation such as enhanced secretion of neuro-
trophic factors to lessen neuronal death and restore tis-
sue homeostasis. In this scenario, late stage microglia
activation in the retina, and especially in the contralat-
eral eye, might potentially be neuroprotective [32]. On
the other hand, early microglia response clearly seems to
be associated with the initiation of neurodegenerative
processes (reviewed in [36–38]). However, a question
that remains unsolved is how the stimulus of micro-
glial activation is transferred from the injured to the
unaffected eye. One hypothesis suggests that degeneration
of optic nerve axons in the lateral geniculate nucleus
might affect the synaptic terminals of RGCs from the
contralateral eye, possibly resulting in a retrograde trans-
mission of the neurodegenerative stimulus [39]. Another
possibility is that increased MHC-II expression and anti-
gen presentation in the optic nerve head after iOHT leads
to priming of T lymphocytes, which in turn are able to ac-
tivate microglia cells in the contralateral eye [32]. In an-
other study, the same authors demonstrate increased
numbers of Iba1+/MHC-II+ cells and rare Iba1+/CD68+
cells in the contralateral eye, suggesting an activation of
the “M1” microglial phenotype. However, a decline in
RGC density in the contralateral eye could not be deter-
mined in this study [33]. The theory of an involvement of
T lymphocytes to induce a proinflammatory stimulus to
the retina has received additional support by a recent
study in which T lymphocytes from glaucomatous animals
were transferred into healthy recipients. The recipients
demonstrate a mild activation of microglia cells and a sig-
nificant loss of RGC [40]. All these studies indicate the in-
volvement of the immune system in the pathology of RGC
loss, but additional experiments are needed to investigate
the mechanism of contralateral microglia activation after
unilateral injury in more detail.
IgG autoantibodies occur naturally in the healthy
retina, but an increased number of retinal IgG autoanti-
body depositions have been observed in human glau-
comatous retina [18], animal models of experimental
autoimmune encephalomyelitis [24], and autoimmune
glaucoma [25, 41]. Analogously, significantly increased
amounts of IgG autoantibody accumulations were found
bilaterally in retinas after unilateral iOHT (Fig. 5). Some
autoimmune diseases affecting the central nervous sys-
tem such as systemic lupus erythematosus or multiple
sclerosis (MS) feature a direct involvement of specific
immunoglobulins [13]. In the case of MS, autoantibodies
against proteins of the myelin sheath directly cause de-
generation of the axon [42, 43]. It has also been shown
that autoantibodies act as part of the classical comple-
ment pathway and are involved in the pathobiology of
AD (reviewed in [44]) and that specific autoantibodies
against amyloid-ß deteriorate neuronal function [45].
These findings clearly demonstrate the harmful role of
autoantibodies in neurodegenerative disorders. In glau-
comatous subjects, as well as in several animal models
of glaucoma, activation of the complement system has
been shown [46, 47], but it has not been demonstrated
that autoantibodies and C1q are co-located in the retina.
Furthermore, a recent paper describes that the absence
of immunoglobulins neither inhibits binding of C1q nor
prevents RGC loss in an animal model of glaucoma [23].
These data do not support the argument that autoanti-
body accumulation in glaucoma is detrimental, and it
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might also be possible that some immunoglobulins
found in glaucoma have beneficial functions (reviewed
in [10, 11]). Unfortunately, the nexus on the function of
immunoglobulins found in glaucomatous retina cannot
yet be determined unequivocally.
Humoral immune response
The overall aim of this study was the question whether
or not a systemic immune response is initiated by RGC
loss due to increased IOP and, more precisely, if the
humoral immune response is correlated with optic
nerve axon loss. Manipulation of the IOP elicits a sig-
nificant increase of immunoreactivities against gluta-
thione S-transferase, spectrin (alpha-fodrin, respectively),
and transferrin compared with control animals. Likewise,
an increased immunoreactivity of these autoantibodies,
except transferrin, has been described for patients suf-
fering from glaucoma [48, 49], indicating the close
analogy of this experimental animal model to glaucoma.
More interestingly, these three proteins are found to be
involved in the pathobiology of other neurodegenerative
diseases.
Glutathione S-transferase (GST) belongs to a family of
multifunctional enzymes that act alone or along with en-
zymes within most mammalian organs and their cells to
reduce superoxide radicals, hydroxyl radicals, and perox-
ynitrites [50]. The occurrence of GST protein in the hu-
man retina is thought to be neuroprotective [51, 52]. A
study demonstrated that serum antibodies against the
GST antigen are present in 52 % of patients with either
primary open angle glaucoma or normal tension glau-
coma. The occurrence of serum GST autoantibodies
might be explained as an epiphenomenal event due to
neurodegenerative processes in retinal ganglion cells
undergoing apoptosis [48].
Spectrin is a member of the F-actin-crosslinking pro-
tein superfamily and is equivalent to alpha-fodrin [53].
This large, cytoskeletal and heterodimeric protein is in-
volved in the cell cycle, cell adhesion, cell spreading,
DNA repair, and intracellular traffic. Spectrin serves as a
substrate of caspase-3 and calpain in neurons, leading
to structural disorganization and membrane blebbing,
an attribute of cells undergoing apoptosis [54]. Inter-
estingly, anti-spectrin antibodies are suspected to be
involved in the pathogenesis of a variety of neurode-
generative and autoimmune diseases such as AD [55],
Sjögren syndrome [56], MS, and normal tension glau-
coma [49], where elevated anti-spectrin immunoreac-
tivities could be shown. During optic neuritis, the
most common initial symptom of MS, higher levels of
calpain led to elevated levels of spectrin cleavage [57].
It is therefore conceivable that the occurrence of
serum antibodies against spectrin might be a result of
major cleavage of spectrin in autoimmune diseases.
Transferrin is a serum iron-binding protein that is
produced in the liver. It interacts with the transferrin re-
ceptor located on the cellular surface for delivery of
redox active iron (Fe3+) molecules into the cell via
receptor-mediated endocytosis in a pH-dependent man-
ner [58]. Lower levels of transferrin after the initiation of
inflammation due to infection, tissue injury, trauma, or
immunological disorders lead to low levels of serum
iron, which prevents microbial growth and is therefore
beneficial for the infected organism [59]. In AD, the iron
homeostasis dysregulation might lead to intracellular
iron accumulation and to a rise of oxidative stress [60].
Very little data exists regarding the role of anti-
transferrin antibodies in neurodegenerative diseases.
However, in this study, elevated levels of anti-transferrin
antibodies were identified, which might be an indicator
for elevated serum levels of transferrin protein.
Moreover, the correlation analysis highlights that the
loss of axons in the optic nerve in vivo is linked to the
humoral immune response: The higher the immunoreac-
tivity of autoantibodies against GST, spectrin, and trans-
ferrin, the lower axonal survival.
Effects of B lymphocyte inhibition on RGC survival
Glaucoma is a complex disease with many contributing
pathogenic factors apart from elevated IOP. To better
understand the impact of the autoantibodies in glau-
coma, Belimumab, an inhibitor of the B lymphocytes
activation, was used in this study. Belimumab-treated
animals did not affect IOP elevation, and treated rats
were subjected to a similar ΔIOP than rats without
medication. Although slightly higher numbers of axons
and RGCs were detected in injured eyes of Belimumab-
treated animals compared with the iOHT group, the dif-
ferences are not statistically significant. It is of interest
that the Belimumab-treated group displayed similar
numbers of Iba1+ cells in the retina compared with the
iOHT group (Table 1), but the distribution of microglia
cells within the retinal layers was significantly different.
The majority of microglia cells in this group was found
in the ganglion cell layer, whereas a decreased number
was observed in the inner nuclear layer of fellow and in-
jured eye in iOHT + Belimumab-treated animals. It re-
mains unclear if the increase of the retinal microglia
population is related to retinal infiltration of immune
cells. Iba1 immunostaining does exclusively label not
only microglia but also monocytes [61], and it is not
possible to distinguish between retinal microglia and in-
filtrating cells by Iba1 immunostaining. It is therefore
also conceivable that microglia relocate to the ganglion
cell layer in this group. Changes in the distribution of local
microglia upon activation have been described for mouse
models of age-related macular degeneration (AMD) [62]
and glaucoma [63]. Based upon the observation that the
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shift in the microglial distribution occurred bilaterally
leads to the assumption that this might be a result of the
treatment with Belimumab. Nevertheless, Belimumab
treatment is not sufficient to ameliorate optic nerve axon
loss after iOHT, at least at a dosage of 10 mg/kg, but re-
sults in little improvement in the number of surviving
optic nerve axons. It remains unclear if this marginal res-
cue effect is directly mediated through the drug itself or if
it is a result of the increased microglial activity in the gan-
glion cell layer. Furthermore, injured eyes of Belimumab-
treated animals showed slightly elevated numbers of IgG
autoantibody depositions compared with control and
slightly lower number compared with iOHT injured eyes.
However, those differences were also not statistically sig-
nificant (Table 1). As expected, Belimumab significantly
decreased the IgG titer in iOHT + Belimumab animals
demonstrating the drug’s bioavailability. Likewise, the im-
munoreactivity against GST, spectrin, and transferrin was
also significantly decreased compared with iOHT group.
Overall, the treatment with Belimumab in this study was
not sufficient to significantly affect RGC and axonal loss,
decrease microglial activation, and reduce IgG autoanti-
body depositions. Thus, the role of autoantibodies in the
induction of glaucomatous damage in this experimental
glaucoma model seems limited. On the other hand,
changes in the reactivity of theses autoantibodies are
clearly connected to RGC loss, and therefore, the auto-
antibody profiling may serve as an important biomarker
for glaucoma [10, 11].
In summary, the question about the origin of the de-
scribed antibody immunoreactivities in the iOHT group
should be raised. To date, it remains elusive whether the
elevated antibody reactivities in this animal model
emerge due to recurring pressure fluctuations or if they
are a consequence of the neuronal degeneration of RGCs
and their axons. This intriguing question needs to be the
subject of further studies to understand the role of auto-
antibodies in the pathogenesis not only of glaucoma but
also of other neurodegenerative diseases such as AD,
PD, and Amyotrophic Lateral Sclerosis.
Conclusions
Unilateral intermittent IOP elevations led to a significant
decrease of RGCs and their axons in the optic nerve, ac-
companied by bilateral microglia activation and IgG
autoantibody depositions in the retina. Furthermore, a
systemic immune response due to RGC loss in associ-
ation with an increased IOP could be shown for the
iOHT group with a significant increase of serum IgG reac-
tivities as well as IgG immunoreactivities against glutathi-
one S-transferase, spectrin (alpha-fodrin, respectively),
and transferrin. Immunomodulation using the BAFF-
blocker Belimumab to hinder B lymphocyte activation led
to a significant decrease of serum IgG concentration, a
lower glutathione S-transferase-, spectrin-, and transferrin
immunoreactivities but shows only limited ability to
ameliorate the progression of axonal and RGC loss. This
result limits the detrimental role of autoantibodies in in-
ducing glaucomatous RGC loss but underlines the import-
ance of changes of autoantibody reactivities as a valuable
biomarker. The present study gives insight into the close
relationship between IOP, the immune response, and the
pathology of RGC loss. Nevertheless, more research is
needed in the future to understand the origin of an altered
humoral immune response with focus on cellular in-
teractions in glaucoma and in other neurodegenera-
tive diseases.
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